Table 3 Clinical characteristics of PH infants with and without PS administration.
Variable | Surfactant (n = 30) | N-Surfactant(n = 26) | P-value |
|---|---|---|---|
Age, (mean ± SD weeks) | 28.4 ± 2.4 | 28.8 ± 1.8 | 0.66 |
Gender (male/female) | 11/19 | 19/7 | 0.006 |
Weight, (mean ± SD g)) | 1104 ± 359 | 1168 ± 284 | 0.34 |
Apgar 1 min, (median, quartile) | 6 (4,7.25) | 7.5 (5,9) | 0.09 |
Apgar 5 min, (median, quartile) | 8 (7,9) | 9 (8,9.5) | 0.09 |
Before treatment P/F ratio, (mean ± SD) | 121.7 ± 47.8 | 139.4 ± 71.2 | 0.42 |
24 h After treatment P/F ratio, (mean ± SD) | 256.3 ± 104.2 | 288.9 ± 77.9 | 0.21 |
ABG PH 1 h after birth, (mean ± SD) | 7.237 ± 0.083 | 7.017 ± 0.125 | 0.19 |
Cesarean, n (%) | 21 (70.0) | 26 (53.8) | 0.21 |
Twin, n (%) | 13 (43.3) | 5 (19.2) | 0.10 |
SGA, n (%) | 4 (13.3) | 2 (7.7) | 0.81 |
PROM, n (%) | 5 (16.7) | 6 (23.1) | 0.55 |
GDM, n (%) | 0 | 0 | – |
Abortion history, n (%) | 14 (46.7) | 8 (36.4) | 0.22 |
Gestational infection, n (%) | 8 (26.7) | 3 (11.5) | 0.28 |
PIH, n (%) | 6 (20.0) | 2 (25.0) | 0.35 |
RDS, n (%) | 23 (76.7) | 8 (30.8) | 0.001 |
EOS, n (%) | 16 (53.3) | 14 (53.8) | 0.97 |
NEC, n (%) | 2 (6.7) | 2 (7.7) | 0.71 |
PDA, n (%) | 17 (56.7) | 9 (34.6) | 0.09 |
Pneumothorax, n (%) | 4 (13.3) | 1 (3.8) | 0.44 |
MAS, n (%) | 2 (6.7) | 1 (3.8) | 0.89 |
Milrinone, n (%) | 13 (43.3) | 9 (34.6) | 0.51 |
iNO, n (%) | 14 (46.7) | 6 (23.1) | 0.07 |
Vasoconstrictive drug, n (%) | 12 (40.0) | 13 (50.0) | 0.45 |
Mechanical ventilation, n (%) | 27 (90.0) | 21 (80.8) | 0.33 |
Sildenafil, n (%) | 12 (40.0) | 17 (64.4) | 0.06 |
BPD, n (%) | 9 (30.0) | 17 (65.4) | 0.008 |
ROP, n (%) | 7 (23.3) | 4 (15.4) | 0.68 |
IVH, n (%) | 9 (30.0) | 4 (15.4) | 0.33 |
Death, n (%) | 0 | 0 | – |